Thank You!


logo.gif - 6885 Bytes

38TH ANNUAL MEETING OF THE EASD

Budapest, Hungary

1 - 5 September 2002

Click on the title of the individual session to read the abstracts
Oral Sessions      Poster Sessions
38th EASD Annual Meeting
1 - 5 September 2002

This year the Association received 1,921 abstracts for consideration for inclusion in the Annual Meeting of which 1,250 abstracts were accepted for oral or poster presentation. All abstracts were considered anonymously and were scored by 35 referees in five categories of content:

The Programme Committee Members designed the programme and created Oral and Poster Sessions based upon the anonymous abstracts, without any information on authors or places of work.

The referees were:

C-D. Agardh (S)
C. Boitard (F)
G. Bolli (I)
A.J.M. Boulton (UK)
R.G. Bretzel (D)
A. Ceriello (I)
N. Chaturvedi (UK)
S. Del Prato (I)
R.G. Firth (IRL)
A. Flyvbjerg (DK)
P. Froguel (F)
A. Golay (CH)
R. Gomis de Barbara (E)
L. Groop (S)
H. Heimberg (B)
R.J. Heine (NL)
M. Hod (IL)
G. Jermendy (H)
S. Kumar (S)
T. Linn (D)
O. Madsen (DK)
Y. Le Marchand-Brustel (F)
M. Marre (F)
I. Migdalis (GR)
J. Nerup (DK)
T.J. Orchard (USA)
T. Pieber (A)
I. Raz (IL)
J.-L. Selam (F)
G. Soltész (H)
E. Standl (D)
M.-R. Taskinen (FIN)
A. Vaag (DK)
L. Vileikyte (UK)
J.R. Zierath (S)

 The final programme was selected by the Programme Committee:

A.J.M. Boulton (UK) (Chairman)
C. Boitard (F)
A. Flyvbjerg (DK)
A. Golay (CH)
R. Gomis de Barbara (E)
R.J. Heine (NL)
G. Jermendy (H)
S. Kumar (UK)
T.J. Orchard (USA)
F. Pociot (DK)
I. Raz (IL)
O. Schnell (D)
G. Soltész (H)
J.R. Zierath (S)


logo.gif - 6885 Bytes
38th EASD Annual Meeting
1 - 5 September 2002

38TH ANNUAL MEETING OF THE EASD

Budapest, Hungary

1 - 5 September 2002

Provisional Programme

Scientific Events

Monday - Thursday, 2 - 5 September 2002

       Oral Presentations, EASD Study Group Symposia

       State of the Art Lectures, State of the Art Symposia

       Poster Events / Poster Sessions


Copyright of all abstracts: © Springer-Verlag

Social Events

(included in the Registration Fee of delegates and accompanying persons)


Welcome Reception


Welcome Party "A Taste of Hungary"
Sunday, 1 September 2002 at 19:00

The Welcome Party will take place in the City Park just beyond the Heroes' Square, which was erected to commemorate the thousandth anniversary of the Conquest of Hungary.
During the evening the biggest ever (200) Gypsy Virtuosi Orchestra will give a concert. The evening will also provide an introduction to traditional Hungarian cuisine. Rustic Hungarian dishes with abundant wine will be served during the evening and participants also have the possibility to visit - free of charge - collections of three beautiful historical buildings: the Museum of Fine Arts (which has a valuable Spanish, Venetian and Dutch collection), the Art Gallery, surrounding the Heroes' Square and the Vajdahunyad Castle in the City Park which houses the Museum of Agriculture.

Included in the Registration Fees of participants and accompanying persons; all registered participants and accompanying persons are invited.


Farewell Reception

Farewell Wine Festival
Thursday, 5 September 2002 at 14:30

The Farewell Wine Festival will take place at the Budapest Fair Centre. The Wine Festival will be an excellent opportunity to taste the products of the different wine-growing areas of Hungary. Century-old wine making in Hungary has a glorious history: Hungarian wines have been drunk in the civilised world for centuries. Aszú of Tokaj have graced the table of renowned princes in Europe, which are said to be the nectar necessary for the conception of a male heir. For example, Aszú of Tokaj was called "King of wines, wine of Kings" by Louis XIVth, the Sun King of France. Wines from Eger, Neszmély, Szekszárd, Villány, Gyöngyös and Sopron, the volcanic area of Lake Balaton have always been good ambassadors of its culinary treasury, maintaining Hungary's position as the third senior wine producing country in Europe. Participants cane make "comparative tests" among the various sorts of wine.

Included in the Registration Fees of participants and accompanying persons; all registered participants and accompanying persons are invited.



Monday, 2 September 2002

09:00 - 09:30     Balaton Hall
Opening Ceremony


09:30 - 10:30     Balaton Hall
Somogyi Lecture:
Title: Diabetes in the Young: A Paediatric and Epidemiological Perspective
Chairpersons:P.A. Halban (CH), T. Halmos (H)
Speaker:G. Soltész (H)


10:30 - 11:00     Break

11:00 - 12:30     Balaton Hall
OP 1 Diabetic Foot

Chairpersons:
Andrew J. M. Boulton (United Kingdom)
Kristien Van Acker (Belgium)
  1. E. Wertheimer (IL) SIRKO -The skin specific insulin receptor knockout mouse.
  2. A. Piaggesi (I) The effect of pressure relief on the histopathology of neuropathic foot ulcers: a semi-quantitative analysis.
  3. L. Vileikyte (UK) The neuropathy psychosocial inventory: a novel approach to identify factors associated with adherence to foot care.
  4. J. Elliott (UK) Podiatry-led neuropathy ulcer clinics allow effective management of limited time and resources.
  5. J. Franch (E) Diabetic foot in primary health care: a repeated cross-sectional study.
  6. C.N. Dang (UK) Methicillin-resistant staphylococcus aureus in the diabetic foot clinic: the problem is getting worse.


11:00 - 12:30     Yellow Hall
OP 2 Thiazolidinediones - Mode of Action

Chairpersons:
Cornelis J. Tack (The Netherlands)
Itamar Raz (Israel)
  1. A. Gastaldelli (USA) The effect of rosiglitazone on gluconeogenesis in patients with Type 2 diabetes.
  2. A.L. Harte (UK) Suppression by rosiglitazone of the insulin-mediated rise in angiotensinogen expression and angiotensin II secretion in human subcutaneous isolated adipocytes.
  3. N. Goenka (UK) Rosiglitazone blunts the urinary sodium and cGMP response to volume expansion in normal subjects.
  4. Y. Miyazaki (USA) Rosiglitazone therapy improves downstream insulin-receptor signalling in patients with Type 2 diabetes.
  5. K. Hällsten (FIN) Rosiglitazone but not metformin enhances insulin and exercise stimulated skeletal muscle glucose uptake in patients with newly diagnosed Type 2 diabetes.
  6. C.B. Juhl (DK) Influence of thiazolidinedione (rosiglitazone) treatment on beta-cell function in Type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility.


11:00 - 12:30     Red Hall
OP 3 Cardiovascular Risk Factors

Chairpersons:
Nora Hosszufalusi (Hungary)
Oliver Schnell (Germany)
  1. J.A. Pinies (E) Cardiovascular risk factors and risk level of coronary heart disease in known Type 2 diabetes in the Basque Country (Spain).
  2. C.C. Chow (China) Lipid profile in Chinese Type 2 diabetic subjects in relation to cardiovascular mortality, glycaemic control and anthropometric parameters.
  3. E. Brocco (I) Low HDL-cholesterol but not high triglycerides levels are related to intima-media thickening in recently diagnosed Type 2 diabetes.
  4. E. Cosson (F) Arterial disease rather than classical cardiovascular risk factors as predictor of cardiovascular events in asymptomatic patients with diabetes.
  5. M. Sacco (I) Prevention of cardiovascular events with low-dose Aspirin and vitamin E in Type 2 diabetic patients: results of the PPP trial.
  6. G. Magro (I) Insulin resistance is associated to in-stent restenosis in Type 2 diabetic patients.


11:00 - 12:30     Green Hall
OP 4 Functional Genomics

Chairpersons:
Juleen Zierath (Sweden)
Francesco Beguinot (Italy)
  1. K. Persson (S/I) Mice with deletion of the PAC1 receptor display glucose intolerance due to combination of islet dysfunction and impaired insulin sensitivity.
  2. M. Kvist Reimer (S) Galanin null mutation is associated with glucose intolerance in mice.
  3. N.A. Thornberry (USA) Role of Dipeptidyl Peptidase IV (DP-IV) in metabolic control.
  4. A. Davies (UK) The identification of a novel orphan G-protein coupled receptor expressed in rat hypothalamus.
  5. S. Efendic (S) Evidence that estrogen receptor-a plays an important role in the regulation of glucose homeostasis in mice.
  6. A. Cederberg (S/I) Adipocyte overexpression of the winged helix gene, FOXC2, results in markedly increased insulin sensitivity in mice.


11:00 - 12:30     White Hall
OP 5 Diabetes in Childhood: from Type 1 to Type 2

Chairpersons:
Gyula Soltész (Hungary)
Edith Schober (Austria)
  1. R.W. Holl (D/A) 7 years of continuous nationwide quality monitoring in pediatric diabetology demonstrates major changes in the process of diabetes care, but little effect on outcome.
  2. D. Dunger (A/B/Croatia/CZ/FIN/D/UK/NL/ZA/CH) Insulin glargine provides long-term effective glycaemic control in children and adolescents with Type 1 diabetes.
  3. M. Vanelli (I) Direct measurement of 3-beta-hydroxybutyrate (3HB) enhances the management of Diabetic ketoacidosis (DKA) in children and reduces time and costs of treatment.
  4. J. Peczynska (PL) Growth hormon (GH), insulin-like growth factor (IGF-1) and insulin-like growth factor binding protein (IGFBP-3) in young diabetic patients with the onset of diabetic angiopathy.
  5. W.S. Cutfield (NZ) Prepubertal children are at high risk of intramuscular insulin administration based upon subcutaneous fat thickness.
  6. A.M. Körner (H) Early signs of cardiovascular involvement in children with Type 2 diabetes mellitus.


11:00 - 12:30     Orange Hall
OP 6 Genetics of Type 1 Diabetes Mellitus

Chairpersons:
Klaus Badenhoop (Germany)
Jorma Ilonen (Finland)
  1. F. Pociot (DK) Novel analytical methods reveal interaction of several genetic T1DM susceptibility loci.
  2. L. Field (CAN) Evidence that the locus for coxsackie B virus receptor predisposes to Type 1 diabetes.
  3. R. Bergholdt (DK) Fine-mapping of a genetic region on chromosome 21 showing linkage to T1DM.
  4. A-P. Laine (FIN) A linkage study of 12 IDDM susceptibility loci in Finland.
  5. V.V. Nosikov (RU) A novel locus os novel locus of susceptibility to diabetes Type 1 was identified on chromosome 11p13 using Russian multiplex families.
  6. R. Hermann (FIN) Temporal changes in the frequencies of HLA genotypes in Type 1 diabetes patients reflect the importance of environmental factors in disease pathogenesis.


12:45 - 14:45 Poster Events and Lunch

12:45 - 13:45     Poster Event A
13:45 - 14:45     Poster Event B


15:00 - 16:30     Balaton Hall
OP 7 Metabolic Syndrome

Chairpersons:
Tamás Halmos (Hungary)
Michael Stumvoll (Germany)
  1. B.J. Balkau (F) The frequency and incidence of the NCEP (National Cholesterol Education Program) metabolic syndrome in the French D.E.S.I.R. study.
  2. I. Gause-Nilsson (S) The metabolic syndrome is present in one out of five subjects in an elderly Swedish population.
  3. L.A. Costa (Brazil) Aggregation of features of metabolic syndrome increases the proportion of diabetic complications in patients with Type 2 diabetes mellitus.
  4. S. Svacina (CZ) Quantification of diabetes and metabolic syndrome relationship in obese using cluster and factor analysis.
  5. J.D. Krebs (UK) Elevated sialic acid predicts features of the metabolic syndrome.
  6. T. Hidvégi (H) Serum lipid alterations of subjects screened for metabolic syndrome in primary health care.


15:00 - 16:30     Yellow Hall
OP 8 Insulin and Amylin Delivery

Chairpersons:
Philip D. Home (United Kingdom)
Ole Schmitz (Denmark)
  1. P. Modi (Ecuador) Oral insulin spray (Oralin) as meal insulin for treatment of Type 1 diabetes.
  2. L. Want (USA) Pramlintide treatment for 4 weeks reduced postprandial glucose, glucagon and triglyceride excursions in patients with Type 1 diabetes treated intensively with insulin pumps.
  3. J.S. Skyler (USA/CAN) Efficacy and safety of inhaled insulin (Exubera®) compared to subcutaneous insulin therapy in an intensive insulin regimen in patients with Type 1 diabetes: results of a 6-month, randomised, comparative trial.
  4. S.E. Fineberg (USA) Results of insulin antibody monitoring during phase II and phase III clinical studies of inhaled insulin (Exubera®) in patients with Type 1 or Type 2 diabetes.
  5. J.H. DeVries (NL) Continuous subcutaneous insulin infusion improves glycaemic control and quality of life in Type 1 diabetes patients with long standing poor glycaemic control - a randomized trial.
  6. M. Kvapil (CZ/PL/DK/RU) In patients with poorly controlled Type 2 diabetes, biphasic insulin aspart 30 combined with metformin provides better glycaemic control than sulphonylurea/metformin combination.


15:00 - 16:30     Red Hall
OP 9 Psychological and Educational Issues

Chairpersons:
József Fövenyi (Hungary)
Alain Golay (Switzerland)
  1. J.C. Keers (NL) Effects of a multidisciplinary intensive education programme for diabetes patients with prolonged self-management difficulties.
  2. E.E. Agardh (S) Psycho-social stress factors associated with Type 2 diabetes among middle-aged Swedish women.
  3. T. Hrachovinova (CZ) Relationship between resilience to stress, depression, anxiety and diabetes control.
  4. M.R. Gordeladze (Georgia) Differential diabetes education program for children and adolescents - its role and results.
  5. M. Pibernik-Okanovic (Croatia) Effects of an empowerment-based psychosocial intervention on quality of life and metabolic control in Type 2 diabetic patients.
  6. J.V. Sakharova (Ukraine) Influence of non-verbal intellect grade (non-v.IG) for effective education.


15:00 - 16:30     Green Hall
OP 10 Glucose Transport

Chairpersons:
Yannick Le Marchand-Brustel (France)
Jürgen Eckel (Germany)
  1. D. Konrad (CAN) A new animal model to analyze the contribution of GLUT4 activation in insulin-stimulated glucose uptake in intact cells and tissue.
  2. D. Torok (CAN) GLUT4 is the major transporter isoform responsible for basal and insulin-stimulated glucose uptake in L6 myotubes overexpressing a myc-GLUT4 and in primary adipocytes, but not 3T3-L1 adipocytes.
  3. F. Giorgino (I) Role of Ubc9 in the development of insulin-responsive glucose transport during adipocyte differentiation.
  4. A. Krook (S) Evidence for 2 distinct pathways for activation of MEF2-DNA binding in primary cultures of human skeletal muscle.
  5. E. Karnieli (IL) Peroxisome proliferator-activated receptor gamma represses GLUT4 promoter activity in primary adipocytes, and this effect is alleviated by rosiglitazone.
  6. J.H. de Haan (NL) Both a short bout of exercise and ischemia strongly increase glycogen synthesis rate during hyperinsulinemia in humans. A study using 13C- and 31P- MRS.


15:00 - 16:30      White Hall
OP 11 Diabetes and the Heart

Chairpersons:
Güábor Pogátsa (Hungary)
Eberhard Standl (Germany)
  1. G.C. Linnemeier (USA/Bahamas/Brazil/IRL) Enhanced external counterpulsation provides angina relief in diabetic patients - a one year clinical outcome study from the International EECP patient registry.
  2. L. Vaur (F) Development of congestive heart failure in high risk Type 2 diabetic patients.
  3. H.W. Ghobrial (F) Management of acute myocardial infarction (AMI) in diabetic patients in intensive care units (ICU) in France: results from the USIC 2000 study.
  4. I. Stranders (NL) Admission plasma glucose as risk indicator of long-term mortality after acute myocardial infarction in patients with and without diabetes.
  5. Å. Tenerz (S) Long term prognosis in non-diabetic patients with an acute myocardial infarction depends on basal glucometabolic status.
  6. C. Thilo (D) Coronary calcium in asymptomatic Type 1 diabetic patients - a study with multislice spiral CT.


15:00 - 16:30      Orange Hall
OP 12 Progenitors of Beta-Cells

Chairpersons:
Claes Hellerström (Sweden)
Bernat Soria Escoms (Spain)
  1. N. Wierup (S) The ghrelin cell. A novel developmentally regulated islet cell.
  2. M-A. Huotari (FIN) The IIIb isoform of fibroblast growth factor receptor 2 is required for proper growth and branching of pancreatic ductal epithelium but not for differentiation of exocrine or endocrine cells.
  3. H. Jahr (D) Bone marrow cell-induced beta-cell regeneration in streptozotocin-diabetic mice.
  4. E.J.R. Arany (CAN) Rat islet regeneration results from the regulation of distinct sources of progenitor cells and induction of a cascade of transcription factors in the neonatal rat.
  5. I. Rooman (B) Islet neogenesis in the regeneration model of rat pancreatic duct ligation requires endogenous gastrin action via CCK2 receptors.
  6. K. Umezawa (J) Induction of P38-mediated insulin production in pancreatic acinar carcinoma cells by the alkaloid conophylline.


16:30 - 17:00     Break


17:00-18:00     Balaton Hall
State of the Art Lecture

Title:Prevention of Type 1 Diabetes: Results of the ENDIT Trial
Chairperson:J. Nerup (DK)
Speaker: E. Gale (UK)


17:00-18:00     Yellow Hall
State of the Art Lecture

Title:Atherosclerosis and Inflammation: Chicken or Egg?
Chairperson:H. Yki-Järvinen (FIN)
Speaker: J.C. Fruchart (F)


17:00- 18:00     Green Hall
State of the Art Lecture

Title:Update on the Pathogenic Mechanisms in Diabetic Retinopathy
Chairperson:M. Porta (I)
Speaker:H.- P. Hammes (D)


17:00-18:00     White Hall
State of the Art Lecture

Title:Wound Healing in Diabetes
Chairperson:A.J.M. Boulton (UK)
Speaker:I. Cohen (USA)


Tuesday, 3 September 2002


8:30 - 10:30     Balaton Hall
ADA / EASD State of the Art Symposium

Title:Therapeutic Approaches to the Treatment of Type 2 Diabetes and Obesity
Chairpersons:F. Kaufmann (USA), S. Kumar (UK)
Speakers:
M.G. Myers (USA):Leptin Signalling in Obese and Diabetic Mouse Models
B.B. Zhang (USA)Insulin Mimetics in the Treatment of Type 2 Diabetes
H. Lebovitz (USA)Clinical Potential of GLP-1 and its Analogues
F. Pi-Sunyer (USA)Treating Obesity in Diabetes


8:30 - 10:30     Yellow Hall
DOIT Study Group Symposium

Title:Informatics in the Delivery of Diabetes Care
Chairperson:N. Vaughan (UK)
Speakers:
R. Engelbrecht (D)Electronic Records and Information Systems
M. Albisser (USA)Decision Support Systems
R. Bellazzi (I)Telemedicine Solutions
R. Young (UK)Assessing the Quality of Care


8:30 - 10:30     Green Hall
Joint Symposium of the 4 EASD Study Groups related to Complications:
NEURODIAB, Nephropathy, Retinopathy, and Foot Study Groups

Title:Diabetic Complications
Chairpersons:B. Feldt-Rasmussen (DK), P. Kempler (H)
Speakers:
D. Ziegler (D)Diabetic Neuropathy: State of the Art
A.K. Sjølie (DK)Medical Treatment of Diabetic Retinopathy
L. Gnudi (UK)Mechanism of Renal Damage in Diabetes Mellitus: New Data from in vivo and in vitro Experimental Findings
M. E. Edmonds (UK) Advances in the Diabetic Foot


8:30 - 10:30     White Hall
State of the Art Symposium

Title:Genetic Testing for the Prediction of Diabetes
Chairpersons:F. Pociot (DK), P. Froguel (F)
Speakers:
J. Ilonen (FIN)Type 1 Diabetes
L. Groop (S)Type 2 Diabetes
A. Hattersley (UK)MODY
S. Holm (UK)Ethics of Genetic Testing


8:30 - 10:30




Orange Hall
State of the Art Symposium

Title:Controversies in Beta-Cell Stimulating Pathways
Chairpersons:R. Gomis de Barbara (E), G. Rutter (UK)
Speakers:
C. Wollheim (CH)K-ATP Dependent and Independent Pathways
J.C. Henquin (B)K-ATP Dependent and Independent Pathways
I. Leibiger (S)Insulin vs. Glucose Signalling in the Beta-Cell
C. Rhodes (USA)Insulin vs. Glucose Signalling in the Beta-Cell


10:30 - 11:00     Break


11:00 - 12:30     Balaton Hall
OP 13 New Devices for Glucose Monitoring

Chairpersons:
Jean-Louis Selam (France)
Antonio Tiengo (Italy)
  1. P. Diem (CH) Clinical results with the continuous viscometric glucose sensor gluconline.
  2. H.O. Steinberg (USA) Clinical comparison between a novel non-invasive and the conventional invasive method of glucose determination during variable-step hyper- and hypoglycemic clamp studies.
  3. S.V. Edelman (USA) Continuous glucose sensing with a long-term subcutaneous implant in patients with Type 1 diabetes.
  4. T. Koschinsky (D) Blood glucose alternative site testing is related to differences of upper dermal blood flow.
  5. R.M. Bergenstal (USA) An assessment of alternative-site blood glucose monitoring - the impact of physical activity and site preparation.
  6. P. Böhme (F) Accuracy of portable glucose meters during the last decade: a 24000 samples study.


11:00 - 12:30      Yellow Hall
OP 14 Neuropathy

Chairpersons:
Rayaz A. Malik (United Kingdom)
Peter Kempler (Hungary)
  1. M.A. Cotter (UK) Extra-mitochondrial production of reactive oxygen species in experimental diabetes: relative importance of NAD(P)H and xanthine oxidases for neurovascular dysfunction.
  2. K. Sugimoto (J) Electrophysiology and morphology in the peripheral nerve associated with chronic hyperinsulinemia and hypoglycemia in rats bearing insulinoma.
  3. L.A. Scott (UK) Sural nerve oxygen saturation is unexpectedly increased in sub-clinical human diabetic neuropathy.
  4. M. Taskiran (DK) Decreased myocardial perfusion reserve in diabetic autonomic neuropathy.
  5. T.M. Gibson (UK) Impaired gastric fundus innervation in experimental diabetes: effects of candesartan treatment.
  6. T.P. Didangelos (GR) Effect of quinapril or losartan or their combination on diabetic autonomic neuropathy and left ventricular function.


11:00 - 12:30      Red Hall
OP 15 Type 2 Pathophysiology: from Experimental Models to the Humans

Chairpersons:
Philippe Vague (France)
Stefano Del Prato (Italy)
  1. R.N. Kulkarni (USA) ß-cell-specific double knockout of the insulin- and IGF-1-receptors leads to severe early-onset diabetes.
  2. J.V. Silha (CAN) Impaired sensitivity to insulin and insulin-like growth factor-I in insulin-like growth factor binding protein-3 transgenic mice.
  3. K. Maedler (CH) Glucose-induced beta-cell production of interleukin-1beta contributes to glucotoxicity in human pancreatic islets.
  4. A. Clark (UK) Proliferation and apoptosis in human islet development: apoptosis is associated with islet amyldoidosis in Type 2 diabetes.
  5. P. Marchetti (I) Function and survival of islets prepared from the pancreas of Type 2 diabetic patients.
  6. X.J. Li (China) True insulin and proinsulin profile in normal glucose tolerant first-degree relatives in familial Type 2 diabetic pedigrees.


11:00 - 12:30     Green Hall
OP 16 Physical Exercise: From Experimental to Clinica

Chairpersons:
John Wahren (Sweden)
Veikko A. Koivisto (Germany)
  1. R. Pold (DK) Long-term AICAR administration and exercise prevent diabetes in ZDF rats.
  2. F. Dela (DK) Time course of GLUT4 and AMPK protein expression in human skeletal muscle during 1 month of physical training.
  3. J.W. Helge (DK) Training and insulin sensitivity: effects of muscle phospholipid and triacylglycerol fatty acid composition and total muscle triacylglycerol content.
  4. E. Cauza (A) Effects of resistance training on glycemic control in Type 2 diabetes mellitus.
  5. T. Østergård (DK) Improved insulin sensitivity, but no relationship between change in physical fitness and insulin sensitivity after 10 weeks of aerobic exercise in healthy first-degree relatives of Type 2 diabetic patients.
  6. D.W. Dunstan (AUS) Effects of supervised and home-based high-intensity resistance training in older persons with Type 2 diabetes. A 12-month randomised controlled trial.


11:00 - 12:30     White Hall
OP 17 Pathogenetic Mechanisms of Cardiovascular Disease

Chairpersons:
Nicolae D. Hancu (Romania)
Marja-Riitta Taskinen (Finland)
  1. W.E. Allen (UK) Elevated glucose concentration potentiates vascular smooth muscle cell chemotaxis via phosphoinositide 3-kinase-p110ß, protein kinase B and protein kinase CßIII.
  2. S.B. Solerte (I) Human insulin up-regulates the release of Vascular Endothelial Growth Factor (VEGF) from immune cells in hyperinsulinemic microalbuminuric Type 2 diabetic patients.
  3. L. Rawling (UK) Neutrophil actin assembly and trafficking of cell surface antigens is impaired in first-degree relatives of patients with Type 2 diabetes.
  4. M.N. Lauer (UK) AGT, PAI and resistin gene expression in human epicardial fat.
  5. D. Pisarczyk-Wiza (PL) The influence of postprandial state on the polymorphonuclear neutrophils function in Type I diabetic patients.
  6. Y. Suzuki (J) Aldehyde dehydrogenase 2 genotype and maternal inheritance of diabetes in patients with diabetic renal failure.


11:00 - 12:30     Orange Hall
OP 18 Pathophysiology of Type 1 Diabetes Mellitus

Chairpersons:
Hubert Kolb (Germany)
Didac Mauricio (Spain)
  1. S. Ferret (F) iMacs deficiency in NOD mice: implication in cyclophosphamide-induced diabetes?
  2. A.K. Cardozo (B) IL-1ß and IFN-g induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice.
  3. C. Mora (USA/E) Role of CD4 T cells in the induction of diabetes.
  4. J.-M. Bach (F) Diabetes acceleration in NOD mice after DNA immunization encoding GAD65: involvement of cytolytic CD8 T-cells and Th2/3 CD4 T-lymphocytes.
  5. E. Anastasi (I) Notch3 transgenic mice are protected against experimental autoimmune diabetes and display enhanced generation of T regulatory cells.
  6. E. Hatziagelaki (GR) Intracellular IFN-g production and IL-12 serum levels in latent autoimmune diabetes in adults (LADA) and in Type 2 diabetes.


12:45 - 14:45     Poster Events and Lunch

12:45 - 13:45      Poster Event C
13:45 - 14:45      Poster Event D


15:00 - 16:30      Balaton Hall
OP 19 Health Care Delivery

Chairpersons:
Didier J. M. Halimi (France)
Pesach Segal (Israel)
  1. F.X. Cos (E) Improvement in quality of diabetes care in primary health care centres: a seven years experience.
  2. S. Eberl (D) Longitudinal evaluation of risk profiles within a population based quality management programme.
  3. R.J. Gfrerer (A/D) Are we putting evidence based medicine into clinical practice?
  4. I. Rakovac (A/D) Impact of quality management on process quality and intermediate outcome of antihypertensive treatment.
  5. J. Lee (UK) The Alphabet POEM audit project: practice of evidence based medicine audit tool to measure implementation of evidence based strategies to reduce diabetes complications.
  6. K.L. Pedula (USA) The impact of age at diagnosis on cost of medical care in subjects with Type 2 diabetes.


15:00 - 16:30      Yellow Hall
OP 20 Lipid Abnormalities

Chairpersons:
László Gerö (Hungary)
Gerald H. Tomkin (Ireland)
  1. B. Feldt-Rasmussen (DK) Increased transvascular low density lipoprotein transport in patients with Type 2 diabetes mellitus.
  2. A. Jirkovská (CZ) Is the respiratory burst of polymorphonuclear leukocytes related to low-density-lipoprotein oxidation?
  3. G. Sartore (I) Dietary fatty acids, lipoproteins and insulin resistance.
  4. N. Beeharry (UK) Fatty acid protection against apoptosis reversed by PI3-K inhibitor in RINm5F cells.
  5. B. Vergès (F) The expression of LDL-receptors on cell surface is reduced, in not well controlled Type 2 diabetes and normalized after insulin treatment.
  6. N. Wiernsperger (F) Acute hypertriglyceridemia is associated with arteriolar vasodilation in rat skeletal muscle.


15:00 - 16:30      Red Hall
OP 21 GLP-1 Analogues and Exendin-4 in Type 2 Diabetes Mellitus

Chairpersons:
Michael A. Nauck (Germany)
Robert J. Heine (The Netherlands)
  1. M.E. Trautmann (D) Once daily administration of LY307161 SR, a sustained release formulation of a GLP-1 analogue, substantially reduces fasting and daytime glucose levels in patients with Type 2 diabetes.
  2. B.E. Patterson (D) The Pharmacokinetics (PK) and Pharmacodynamics (PD) of LY307161 SR, a sustained release formulation of a GLP-1 analog, administered subcutaneously to patients with Type 2 diabetes.
  3. K. Taylor (USA) Continuous subcutaneous infusion of AC2993 (synthetic exendin-4) provides sustained day-long glycemic control in patients with Type 2 diabetes.
  4. M. Fineman (USA) 28 days of treatment with AC2993 (synthetic exendin-4) improved glycemic control in patients with Type 2 diabetes concomitantly treated with metformin (met) and/or sulfonylurea (sfu).
  5. D. Kim (USA) AC2993 (synthetic exendin-4) lowered fasting glucose concentrations through suppression of glucagon and dose dependent insulinotropism in patients with Type 2 diabetes.
  6. M. Saad (USA) The effect of NN2211, a long-acting GLP-1 derivative, on glycemic control and body weight in obese patients with Type 2 diabetes.


15:00 - 16:30      Green Hall
OP 22 Insulin Receptor Substrates

Chairpersons:
Emmanuel Van Obberghen( France)
Martin Myers (USA)
  1. M. Sadagursky (IL) IRS1 and IRS2 have distinct roles in primary skin keratinocytes and skin fibroblasts.
  2. A.M. Valverde (E) Essential role of IRS-2 for insulin action in neonatal hepatocytes.
  3. M. Benito (E) Role of Irs-3 in insulin signaling in brown adipocytes.
  4. J.R. Zierath (S/USA) Absence of functional insulin receptor substrate-3 (IRS-3) gene in humans.
  5. V. Sanchez-Margalet (E) Sam68 is recruited in insulin receptor signaling and its expression is induced by insulin stimulation.
  6. S. Perrini (I) Differences of insulin signalling in human adipose tissue depots in vivo.


15:00 - 16:30     White Hall
OP 23 Retinopathy

Chairpersons:
Eva M. Kohner (United Kingdom)
Carl-David Agardh (Sweden)
  1. F. Pomero (I) Effects of protein kinase C activation and inhibition on apoptosis and cell cycle in bovine retinal pericytes cultured in normal and high glucose concentrations.
  2. J. Ruberte (E) Transgenic mice overexpressing IGF-I in eye: a new animal model to study diabetic eye disease.
  3. H-P. Hammes (D) Conditional inactivation of the VEGF gene leads to impaired angiogenesis in the retina.
  4. R. Vasupuram (USA) Aldose reductase inhibitor fidarestat prevents diabetes-induced retinal oxidative strees and VEGF production.
  5. R. Simó (E) Deficit of somatostatin in the vitreous fluid of patients with proliferative diabetic retinopathy: possible role in the etiopathogenesis of diabetic retinopathy.
  6. M.J. Taverna (F) T242T genotype of the NADPH oxidase p22phox C242T polymorphism is associated with decreased risk of severe diabetic retinopathy.


15:00 - 16:30     Orange Hall
OP 24 Prediction and Prevention of Type 1 Diabetes Mellitus

Chairpersons:
Polly J. Bingley (United Kingdom)
Mona Landin-Olsson (Sweden)
  1. J.M. Wahlberg (S) Infections during pregnancy and neonatal period influence diabetes related autoantibody levels in one-year old children.
  2. R. Buzzetti (I) Newborn screening for prediction of Type 1 diabetes genetic risk in continental Italy (Diabfin Study).
  3. T.J. Wilkin (UK) Testing the accelerator hypothesis: Type 1 diabetes presents earlier in the fatter child: the EarlyBird Study.
  4. M. Schlosser (D) Multiple Type 1 diabetes-associated autoantibodies in healthy schoolchildren reflect genetic predisposition for Type 1 diabetes.
  5. F.K. Gorus (B) HLA-DQ restricted progression to clinical onset in antibody-positive first degree relatives of Type 1 diabetic patients.
  6. I.F. Douek (UK) The autoimmune diabetes phenotype across three generations: an extended family study.


16:30 - 17:00      Break

17:00 - 18:00     Balaton Hall Camillo Golgi Lecture

Chairperson:G. Menzinger (I)
Speaker:J. Tuomilehto (FIN)
Title:Prediction and Prevention of Type 2 Diabetes - Episode 2


Wednesday, 4th September 2002


8:30 - 10:30     Balaton Hall
Hypertension Study Group Symposium

Title:Evidence-based Diabetology:
The Case for Anti-Hypertensive Treatment
Chairpersons:P. Nilsson (S), M. Ravid (IL)
Speakers:
R. Cífková (CZ)Hypertension in Diabetes: Risks, Definitions, and Targets
C. Berne (S)Cardioprotection
M. Ravid (IL)Nephroprotection
J. Staessen (B) Stroke Prevention


8:30 - 10:30     Yellow Hall
State of the Art Symposium

Title:The Value of Pharmacological and Non-Pharmacological Interventions for the Prevention of Type 2 Diabetes
Chairpersons:I. Raz (IL), R.J. Heine (NL)
Speakers:
M. Saad (USA)New Results from the DPP
F. Snoek (NL)Implementation of the DPP in Europe: A Psychological Perspective
H. Gerstein (CAN)Do ACE Inhibitors Prevent the Development of Type 2 Diabetes?
K. Matyka (UK)Tackling Childhood Obesity to Prevent Diabetes


8:30 - 10:30     Green Hall
State of the Art Symposium
Title:"Syndrome X" Revisited
Chairpersons:J.R. Zierath (S), S. del Prato (I)
Speakers:
A. Scheen (B)Links Between Obesity and Insulin Resistance
H. Yki-Järvinen (FIN)Is Ectopic Lipogenesis the Cause?
H. Kolb (D)Syndrome X: An Immune Origin?
E. Ferrannini (I)Is it all in the Mind? (CNS/Metabolic)


8:30 - 10:30     White Hall
JDRF / EASD Symposium

Title:Transcription Factors, Beta-Cell Differentiation and Diabetes
Chairpersons:R. Furlanetto (USA), C. Wollheim (CH)
Speakers:
M. German (USA)Transcription Factors and Beta-Cell Differentiation
M. Stoffel (USA)Beta-Cell Transcription Factors and Diabetes: Molecular and Cell Biology
P. Froguel (F)Beta-Cell Transcription Factors and Diabetes: Molecular Genetics


8:30 - 10:30     Orange Hall
State of the Art Symposium

Title:Immune Therapy for Preservation of Residual Beta-Cell Function in Type 1 Diabetes
Chairpersons:L. Madacsy (H), M. Knip (FIN)
Speakers:
P. Pozzilli (I)The Relevance of Residual Beta-Cell Function for Immune Intervention in Type 1 Diabetes
L. Chatenoud (F)Preservation of Residual Beta-Cell Function in Recent Onset of Type 1 Diabetes by Monoclonal Antibodies to CD3
B.O. Roep (NL)Immunomodulation and Preservation of Residual Beta-Cell Function by Antigen Specific Immunisation with the hsp60 peptide p277
J.S. Skyler (USA)Current Approaches to Immune Intervention in Recent Onset of Type 1 Diabetes in North America


10:30 - 11:00     Break


11:00 - 12:30     Balaton Hall
OP 25 Long-Acting Insulin Analogues

Chairpersons:
Geremia B. Bolli (Italy)
Frederik Holleman (The Netherlands)
  1. F. Porcellati (I) Glargine vs NPH as basal insulin in intensive treatment of T1DM given lispro at meals: one year comparison.
  2. E. Standl (D/CH/A/NZ/AUS) One-year safety and efficacy of insulin detemir in subjects with Type 1 diabetes. Favourable weight development and reduced nocturnal hypoglycaemia compared to NPH.
  3. D. Russell-Jones (DK/N/FIN/S/UK/IRL/NL/B/L/F/AUS) Lower and more predictable fasting blood glucose and reduced risk of nocturnal hypoglycaemia with once daily insulin detemir versus NPH in subjects with Type 1 diabetes.
  4. A. Hamann (D) Once-daily insulin glargine is effective and safe in patients with Type 1 diabetes regardless of whether injected before breakfast or dinner, or at bedtime.
  5. A. Fritsche (A/B/FIN/D/IRL/I/NL/P/E/S/CH/TR/UK) Improved glycaemic control and reduced nocturnal hypoglycaemia in patients with Type 2 diabetes with morning administration of insulin glargine compared with NPH insulin.
  6. M. Riddle (USA) Treatment to target in Type 2 diabetes: successful glycaemic control with less nocturnal hypoglycaemia with insulin glargine versus NPH insulin added to oral therapy.


11:00 - 12:30      Yellow Hall
OP 26 Lipid Metabolism

Chairpersons:
Elisabeth R. Trimble (United Kingdom)
Gabor Winkler (Hungary)
  1. J.M. Miles (USA) Systemic and forearm triglyceride metabolism: fate of lipoprotein lipase-generated glycerol and free fatty acids.
  2. R.J. Tunstall (AUS) Effect of elevated lipid concentrations on human skeletal muscle gene expression.
  3. V. Lambadiari (GR) Adipose tissue metabolism in patients with Type 2 diabetes: lipase action in-vivo after a mixed meal.
  4. C.B. Jensen (DK) Young low birth weight men are not more susceptible to a 24-hr low-grade intralipid infusion than matched controls.
  5. H. Vavrinkova (CZ) Effect of captopril on tissue glucose metabolism and insulin action in hereditary hypertriglyceridemic rats.
  6. M.A. Iglesias (AUS) Dual enhancement of muscle fatty acid and glucose uptake following AMPK activation by AICAR in high-fat-fed rats; predominant effects in white muscle.


11:00 - 12:30     Red Hall
OP 27 Genetics of Type 2 Diabetes

Chairpersons:
Torben Hansen (Denmark)
Mark I. McCarthy (United Kingdom)
  1. A.J. Bennett (FIN/UK) Variation at the insulin gene VNTR minisatellite is associated with fasting insulin levels at 31 years: analyses from a large Finnish cohort
  2. E. Carlsson (S/DK) FOXC2 is a candidate gene for insulin resistance.
  3. C.J. Groves (UK/F) Linkage studies of the Type 2 diabetes susceptibility locus on chromosome 1q: combined analysis of 1200 UK and French affected sibpairs.
  4. B. Vozarova (USA) The interleukin-6 (-174) G/C promoter polymorphism is associated with Type 2 diabetes mellitus in American Indians and Caucasians.
  5. C. Menzaghi (I/USA) A haplotype at the adiponectin locus is associated with obesity and other features of the insulin-resistance syndrome.
  6. C.L. de Visser (NL) Familial aggregation of Type 2 diabetes in isolated Dutch population.


11:00 - 12:30      Green Hall
OP 28 Endothelial Dysfunction

Chairpersons:
John Yudkin (United Kingdom)
Ilana Harman-Boehm (Israel)
  1. Y. Tang (Singapore) Activation of protein kinase C possibly mediates the defected CA2+ homeostasis in endothelial cells in prolonged high glucose culture.
  2. M.E. Inkster (UK) Effects of diabetes and angiotensin AT1 receptor blockade with candesartan on endothelium-dependent relaxation in the rat mesenteric vasculature.
  3. S.R. Kashyap (USA) The role of nitric oxide in endothelial dysfunction and insulin resistance in healthy subjects and Type 2 diabetic patients.
  4. A. Behre (D) Endothelial nitric oxide synthase (ecNOS) 4 A/B polymorphism and early atherosclerosis in Type 2 diabetes.
  5. M.M. Sandqvist (S) Increased arterial stiffness in healthy, non-obese subjects with low adipocyte IRS-1 protein expression - a biomarker of insulin resistance and Type 2 diabetes.
  6. M. Artwohl (A) Direct effects of PPARgamma ligands in micro- and macrovascular cells.


11:00 - 12:30      White Hall
OP 29 Mechanisms of Metabolic Regulation

Chairpersons:
John J. Nolan (Ireland)
Laszlo I. Koranyi Hungary)
  1. N. Morgan (UK) Characterisation of peroxisome proliferator-activated receptor expression and function in the endocrine pancreas.
  2. G.D. Tan (UK) Adipose tissue and skeletal muscle metabolism in Type 2 diabetes: in vivo effects of rosiglitazone in humans.
  3. C. Weigert (D) Palmitate activates the hexosamine biosynthetic pathway in myotubes of insulin-sensitive and insulin-resistant subjects.
  4. A.C. Rustan (N) Fatty acids modulate leptin and leptin receptor (OB-Rb) gene expression and leptin secretion in cultured human skeletal muscle cells.
  5. C.L. Brand (DK) Synergistic effects of the dual-acting PPARa and g agonist ragaglitazar and the long-acting GLP-1 derivative NN2211 on glycemic control in overtly diabetic ZDF rats.
  6. J-C.C. Mamputu (CAN) Metformin inhibits differentiation of human monocytes into macrophages and foam cell formation.


11:00 - 12:30      Orange Hall
OP 30 Autoimmunity and Diabetes Phenotype

Chairpersons:
Trevor J. Orchard (USA)
Edwin A. M. Gale (United Kingdom)
  1. E. Farcasiu (ROM) Epidemiology of diabetes mellitus in young adults in Bucharest Diabetes Centre, 1995 - 1999.
  2. T.A. Hillier (USA) Are adults with early onset Type 2 diabetes a different clinical phenotype?
  3. T.E.H. Römkens (NL) Latent autoimmune diabetes of the adult: epidemiology in the Netherlands.
  4. I. Shimizu (J) Characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study).
  5. M. Thunander (S) Three year incidence of diabetes mellitus in the Swedish county of Kronoberg with new WHO diagnostic criteria of 1998 and classification by pancreatic autoantibodies and C-peptide.
  6. M. Mikulecky (SL) Positivity of autoantibodies associated with DM 1: seasonal cycling at its manifestation?


12:45 - 14:45     Poster Events and Lunch

12:45 - 13:45     Poster Event E
13:45 - 14:45     Poster Event F


15:00 - 16:15     Balaton Hall
OP 31 Cardiovascular Complications

Chairpersons:
György Jermendy (Hungary)
Richard G. Firth (Ireland)
  1. P. Gæde (DK) The Steno-2 study: intensified multifactorial intervention reduces the risk of cardiovascular disease in patients with Type 2 diabetes and microalbuminuria.
  2. A.J. Scheen (B) Need to optimize cardiovascular prevention in Type 2 diabetic patients: the Belgian OCAPI Survey.
  3. R.M.A. Henry (NL) Arterial stiffness, impaired glucose metabolism and Type 2 diabetes. The Hoorn study.
  4. I. Lemieux (CAN) Low HDL cholesterol without vs. with features of the atherogenic metabolic triad and its impact on IHD risk: the Québec cardiovascular study.
  5. M. Marre (F/D/UK) Low-dose ramipril (1.25 mg/day) does not decrease cardiovascular events in Type 2 diabetes patients with microalbuminuria/proteinuria: the DIABHYCAR (Type 2 DIABetes, HYpertension, CArdiovascular events and Ramipril) study.


15:00 - 16:15     Yellow Hall
OP 32 Hypertension

Chairpersons:
Carl Erik Mogensen (Denmark)
Istvan Wittmann (Hungary)
  1. P.M. Nilsson (S) Hypertension in diabetes - favourable trends in clinical control in repeated national surveys from Sweden.
  2. P. Poulsen (DK) The impact of zygosity and age on 24 hour blood pressure profiles among twins.
  3. L. de Angelis (UK) Elevated aortic pulse wave velocity in subjects with Type 2 diabetes compared with non-diabetic subjects with similar mean arterial blood pressure.
  4. L. Thorn (FIN) Low-dose acetylsalicylic acid (ASA) and blood pressure.
  5. G. Viberti (D/F/E/UK/IRL/ZAF/Mexico/Brazil/ARG/TR/MAR/Tunesia/H/PL/CZ/SLO/A/CZ/B/NL) Treatment based on a very low dose combination of perindopril and indapamide reduces albuminuria more effectively than enalapril in hypertensive Type 2 diabetic patients: the PREMIER study.


15:00 - 16:15     Red Hall
OP 33 Adipocytokines and Insulin Action

Chairpersons:
Hans-Ulrich Häring (Germany)
Roy Taylor (United Kingdom)
  1. D. Dietze (D) Impairment of insulin signalling in human skeletal muscle cells by co-culture with human adipocytes.
  2. P.G. McTernan (UK) Depot-specific expression of resistin in human adipose tissue and regulation of resistin secretion by insulin and rosiglitazone in human subcutaneous adipocytes in vitro.
  3. M.F. Fisher (UK) Depot specific mRNA and protein expression of adiponectin in human adipose tissue.
  4. S. Ait El Mkadem (B) Leptin treatment corrects plasma adiponectin levels in ob/ob mice.
  5. B. Ahrén (S/USA/CAN) The adipocyte hormone, acylation stimulating protein, stimulates insulin secretion from Ins-1 cells.


15:00 - 16:15     Green Hall
OP 34 Epidemiology

Chairpersons:
Zsuzsa Kerenyi (Hungary)
John H. Fuller (United Kingdom)
  1. K.O. Kyvik (DK/S/B/I/E/H/ROM/UK/SL/LIT) Cumulative risk of Type 1 diabetes up to age 30 years across Europe (the IDA study).
  2. P. Jarosz-Chobot (PL) Increasing trend of incidence of diabetes mellitus Type 1 in children aged to15 yrs in Upper Silesia region, Poland, 1989-2000.
  3. J. Rosenbauer (D) The overall risk of Type 1 diabetes in children is increasing whereas age at onset does not change.
  4. A. Casu (I) Type 1 diabetes incidence under 15 years is still increasing in Sardinia. Data from the Eurodiab register 1989-1999.
  5. C. Patterson (Europe) Ecological analysis of trends in the incidence of Type 1 diabetes in European children 1989-2000.


15:00 - 16:15     White Hall
OP 35 Insulin Signaling

Chairpersons:
Johannes A. Maassen (The Netherlands)
Anna Krook (Sweden)
  1. P. Gual (F) Insulin induces the phosphorylation of IRS-1 on three serine residues through different pathways.
  2. C. Huang (CAN) Up-regulation of GLUT4 activity compensates for a translocation defect in an L6 skeletal muscle cell model of insulin resistance.
  3. C.J. Carlson (USA/Argentina) Enhanced basal activation of MAP kinases in adipocytes from Type 2 diabetics: potential role of p38 in the down-regulation of GLUT 4 expression.
  4. N.J. Pearce (UK) Development of glucose intolerance in male transgenic mice overexpressing GSK-3ß on a muscle specific promotor.
  5. H. Eldar-Finkelman (IL) The insulin mimetic action of glycogen synthase kinase-3 inhibitors.


15:00 - 16:15     Orange Hall
OP 36 Transplantation: Clinical and Experimental

Chairpersons:
Rüdiger Landgraf (Germany)
Enric Esmatjes Mombo (Spain)
  1. C. Dieterle (D) 10-years follow-up after successful pancreas transplantation.
  2. P. Fiorina (I) Long term islet function could improve diastolic and endothelial function in uremic IDDM kidney transplanted patients.
  3. L. Makhlouf (USA) Distinct roles of direct and indirect allorecognition pathways in islet allograft rejection in autoimmune and non-autoimmune recipients.
  4. N. Marzo Adam (E) Glycemic regulation in a mouse model of beta-cell hyperplasia: CDK4 (R24C) knock in mice.
  5. B. Kuttler (D) Adenoviral gene transfer of vIL-10 to rat pancreatic islets.


16:15 - 16:45     Break


16:45 - 17:00     Balaton Hall

P.A. Halban (President EASD/EFSD):

EASD / EFSD
Award Ceremony and Presidential Address


17:00 - 18:00     Balaton Hall
Minkowski Lecture

Chairperson:P.A. Halban (CH)
Speaker:B.O. Roep (NL)
Title:T-Cells in the Pathogenesis of Type 1 Diabetes: The Good, the Bad and the Ugly.


18:00          Balaton Hall
38th EASD General Assembly


Thursday, 5th September 2002


8:30 - 9:30     Balaton Hall
State of the Art Lecture

Title:Results of the Heart Protection Study: Lessons for Diabetes Care
Chairperson:T. Orchard (USA)
Speaker:R. Collins (UK)


8:30 - 9:30     Yellow Hall
State of the Art Lecture

Title:New Analyses of Type 1 Genetic Information
Chairperson:E. Gale (UK)
Speaker: J. Nerup (DK)


8:30 - 9:30     Green Hall
State of the Art Lecture

Title:Tissue-Specific Insulin Resistance
Chairperson:A. de Leiva (E)
Speaker:C. R. Kahn (USA)


8:30 - 9:30     White Hall
State of the Art Lecture

Title:Control of Hepatic Blood Glucose Production: Role of PGC-1
Chairperson:A. Vaag (DK)
Speaker:M. Montminy (USA)


9:30 - 10:00     Break


10:00 - 12:00     Balaton Hall
OP 37 Predictors of Type 2 Diabetes Mellitus

Chairpersons:
Jan Skrha (Czech Republic)
Steven Haffner (United Kingdom)
  1. K. Williams (USA/Mexico) Prediction of Type 2 diabetes (DM) using simple measures of insulin resistance: combined results from the San Antonio Heart Study (SAHS), the Mexico City Diabetes Study (MCDS), and the Insulin Resistance Atherosclerosis Study (IRAS).
  2. M. Kikuchi (J) The cause and effect relationship between pancreatic ß-cell impairment or insulin resistance and the natural history of development of Type 2 diabetes in the employees of a trade firm in Tokyo.
  3. A. Bagust (UK/USA) Pattern of long-term beta-cell function deterioration in Type 2 diabetes.
  4. G. Hu (FIN) Occupational, commuting, and leisure time physical activity in relation to risk for Type 2 diabetes in middle-aged Finnish men and women.
  5. O. Vaccaro (I) Na/Li countertransport activity predicts the development of Type 2 diabetes. Results of the Gubbio Study.
  6. J. Spranger (D) Elevated plasma levels of adiponectin independently protect against development of Type 2 diabetes mellitus in apparently healthy people.
  7. M. Norberg (S) Leptin, but not TNF alpha, interleukin-6 or CRP, is a prospective risk marker of Type 2 diabetes independent of obesity.
  8. L.A. Sargeant (Jamaica/UK) Cigarette smoking and risk of Type 2 diabetes: systematic review and meta-analysis of prospective studies.


10:00 - 12:00     Yellow Hall
OP 38 Nephropathy

Chairpersons:
Peter Rossing (Denmark)
Luigi Gnudi (United Kingdom)
  1. D. Burt (UK) P38-mitogen activated protein kinase mediates hexosamine-induced TGFß1 mRNA expression in human mesangial cells.
  2. S. Giannini (I) Effects of TGF-beta 1 and AGEs on high and low affinity VEGF binding sites on glomerular endothelial cells (GENC).
  3. S. Araf (UK) Insulin growth factor-1 induces vascular endothelial growth factor protein secretion via a Src-dependent mechanism in human mesangial cells.
  4. A. Flyvbjerg (DK) Amelioration of long-term renal changes in obese Type 2 diabetic mice by a neutralizing vascular endothelial growth factor (VEGF)-antibody.
  5. P. Logstrup Poulsen (DK) Microalbuminuria is the single most powerful predictor of 25-year mortality in Type 1 diabetes.
  6. G. Penno (I) Microalbuminuria in Type 1 diabetes: factors modulating progression and regression in the Italian cohort of the eurodiab prospective complications study.
  7. G. Vervoort (NL) Atrial natriuretic peptide induced microalbuminuria is associated with endothelial dysfunction in non-complicated Type 1 diabetes patients.
  8. M-A. Gall (DK) Impact of risk factors and their combination on rate of progression to incipient diabetic nephropathy in Type 2 diabetic patients with normoalbuminuria.


10:00 - 12:00     Red Hall
OP 39 Hypoglycaemia

Chairpersons:
Brian M. Frier (United Kingdom)
Stig K. Pramming (Denmark)
  1. M.G. Bischof (A) Brain metabolism during hypoglycemia in healthy and Type 1 diabetic humans.
  2. D. Smith (UK) Modafinil supports cognitive function and symptoms during acute hypoglycaemia in man.
  3. U. Pedersen-Bjergaard (DK) Synergistic effect of plasma angiotensinogen and ACE activity on risk of severe hypoglycaemia in Type 1 diabetes.
  4. B. Thorsteinsson (DK) High ACE activity is associated with high rate of subclinical hypoglycaemia in Type 1 diabetes.
  5. S.P. Lee (UK) Effect of atenolol on QTc interval lengthening during hypoglycaemia in Type 1 diabetes.
  6. K. Akram (DK) Similar risk of severe hypoglycaemia in insulin-treated Type 2 diabetes and Type 1 diabetes with normal awareness.
  7. B.E. De Galan (NL) No role for adrenaline in the pathogenesis of hypoglycaemia-induced counterregulatory failure.
  8. A.E. Stocks (AUS) Can dogs help patients with hypoglycaemia?


10:00 - 12:00     Green Hall
OP 40 Pregnancy and Fetus

Chairpersons:
Gyula Tamas (Hungary)
David R. Hadden (United Kingdom)
  1. J.C. Alcolado (UK) Embryos transferred into a diabetic uterus have a high risk of diabetes.
  2. G. Di Cianni (I) Maternal triglyceride concentrationd and newborn weight in women with normal glucose tolerance.
  3. E. Madarász (H) The determinants of fasting leptin levels and the characteristics of the leptin curves following a 75g oGTT in women with previous Gestational Diabetes Mellitus (GDM).
  4. M.G. Dalfrà (I) An immunological study in women with gestational diabetes and in their newborn.
  5. U.J. Eriksson (S) Linkage study of congenital malformations.
  6. P. Wentzel (S) Antioxidative treatment diminishes dysmorphogenesis caused by inhibition of GAPDH in rat embryos in vitro.
  7. C. Lencioni (I) Insulin secretion and insulin sensitivity in women with previous gestational diabetes: a follow-up study.
  8. J. Lauenborg (DK) Abnormal glucose tolerance after gestational diabetes mellitus - a long-term follow up study of a Danish population.


10:00 - 12:00     White Hall
OP 41 Ectopic Fat and Insulin Resistance

Chairpersons:
Hannele Yki-Järvinen (Finland)
Michael Roden (Austria)
  1. A.W. Herling (D) Association of insulin sensitivity and intramyocellular lipid levels in various rat models of insulin resistance: a 1H-MRS study.
  2. J-M. Ye (AUS) Lipid-induced muscle insulin resistance in vivo: hyperlipidaemia, triglyceride or long-chain acyl-CoA?
  3. E. Pirinen (FIN) Severely reduced white fat deposits without a defect in insulin sensitivity in transgenic mice overexpressing spermidine/spermine N1-acetyltransferase.
  4. M. Haluzik (USA) C57BL/6J vs. FVB/N genetic background strongly influences liver and muscle insulin sensitivity in lipoatrophic A-ZIP/F-1 mice.
  5. A.D. Kriketos (AUS) Gender differences in skeletal muscle triglyceride content, insulin action and adiposity.
  6. A. Virkamäki (FIN) Insulin resistance in healthy subjects is associated with decreased activation of both PI3-kinase and MAP kinase pathways in skeletal muscle.
  7. C. Thamer (D) Subclinical lipid accumulation in the liver is associated with reduced insulin action.
  8. A.M. Poynten (AUS) Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content.


10:00 - 12:00     Orange Hall
OP 42 Insulin Secretion

Chairpersons:
Willy J. Malaisse (Belgium)
Bernhard Portha (France)
  1. T.B. Bödvarsdóttir (DK) NN414, a potent potassium channel opener (KATPCO) selective for SUR1/Kir6.2 improves glucose tolerance in zucker obese rats.
  2. J. Sturis (CH) The SUR1/Kir6.2 selective potassium channel opener NN414 prevents glucose-induced apoptosis in human pancreatic ß-cells.
  3. Y. Tanizawa (J) Overexpression of constitutively activated glutamate dehydrogenase induces insulin secretion through enhanced glutamate oxidation.
  4. C. Mas (CH) Identification of a new gene involved in glucose-stimulated insulin secretion.
  5. R. Roduit (CH/CAN) PPARa, lipid partitioning and glucose stimulated insulin secretion. A study in PPARa-deficient mice.
  6. F.C. Lynn (CAN) Free fatty acids and glucose have counter-regulatory effects on expression on the GIP receptor on clonal ß-cells and pancreatic islets.
  7. E. Renström (S/D/A) Specific activation of first phase glucose-induced insulin secretion by a1C L-type Ca2+ channels in mouse B-cells.
  8. S-i. Gorogawa (J) Role of STAT3 in the endocrine pancreas: an in vivo analysis.


12:15 - 12:30     Balaton Hall

P.A. Halban (President EASD/EFSD):

Introduction of new Honorary Members and
President's address on EFSD activities


12:30 - 13:30     Balaton Hall
Claude Bernard Lecture

Title:Diabetic Dyslipidemia: From Research to Practice
Chairperson:P.A. Halban (CH)
Speaker:M-R. Taskinen (FIN)


13:30          Balaton Hall
Closing Ceremony



Copyright of all abstracts: © Springer-Verlag